GI Pancreatic

Localised

- NeoAdjuvant
  - IRB #11256
    - OHSU Pancreatic IIT
    - Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

- Adjuvant
  - IRB #10540
    - Celgene APACT Trial
      - A phase 3 multicenter, open-label randomized study of nab-Paclitaxel plus Gemcitabine versus Gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma

Metastatic

- First Line Treatment for Advanced or Metastatic Pancreatic Cancer
  - IRB #15304
    - CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

- Second Line Treatment for Advanced or Metastatic Pancreatic Cancer
  - IRB #11733
    - Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

10/4/2016

www.ohsu.edu/cancer